Persistent elevation of CA 19-9 levels in a patient with an extended retroperitoneal dermoid

Anticancer Research

Volumn 19, Issue 4 A, 1999, Pages 2717-2720

  Micke, Oliver ^a   Schafer, U ^b   Willich, N ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b NONE

Author keywords

Benign teratoma; CA 19 9; Dermoid; Retroperitoneum; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; IODINE 131; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; BLOOD LEVEL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; HUMAN; IMMUNOSCINTIGRAPHY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; RETROPERITONEAL TUMOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TERATOMA;

ADULT; ALPHA-FETOPROTEINS; CA-19-9 ANTIGEN; CHORIONIC GONADOTROPIN; DERMOID CYST; FEMALE; HUMANS; MALE; RETROPERITONEAL NEOPLASMS; SEMINOMA; TERATOMA; TESTICULAR NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0032773255     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Ahlstrom KR, Hietala SO, Stigbrand T: Radioimmunodetection of ovarian cancer. Acta Oncol 12: 729-734, 1993.
2. Bares R, Fass J, Bull U, Schumpelick V: Validity of tomographical methods for radioimmunodetection of gastrointestinal tumors. In: New tumor markers and monoclonal antibodies (Klapdor R ed). Stuttgart New York, Georg Thieme Verlag, 1987, pp 470-474.
3. Bellin MF, Duron JJ, Curet P, Dion Voirin E, Grellet J: Primary retroperitoneal teratoma in the adult: correlation of MRI features with CT and pathology. Magn Reson Imaging 9: 263-266, 1991.
4. Bhalla S, Masih K, Rana RS: Teratomas of rare sites: a review of ten cases. J Indian Med Assoc 89: 291-294, 1991.
5. Chatal JF, Fumoleau P, Saccavini JC, Thedrez P, Curtet O, Bianco-Arco A, Chetanneau A, Peltier P, Kremer M, Guillars Y: Immunoscintigraphy of recurrences of gynecologic carcinomas. J Nucl Med 12: 1807-1819, 1987.
6. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McLure M, Rake B, Westrick B, Schoemaker H, Zurawaski R: Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 29: 549-552, 1983.
7. Fateh-Moghadam A, Stieber P: Tumormarker und ihr sinnvoller Einsatz. 2nd ed, Marloffstein-Rathsberg, Jurgen Hartmann Verlag, 1993, pp 36-37.
8. Gattani AM, Mandeli J, Bruckner HW: Tumor markers in patients with pancreatic carcinoma. Cancer 78: 58-62, 1996.
9. Haglund C, Lundin, J, Roberts, PJ: 10 years experience of CA 19-9 in patients with pancreatic cancer. In: Current tumor diagnosis: Applications, clinical relevance, research, trends (Klapdor R ed). Munchen Bern Wien New York, W. Zuckschwerdt Verlag, 1994, pp 803-807.
10. Helfrich G, Klapdor U, Bahlo M, Klapdor R, Schreiber HW: Determination of the tumour markers CA 19-9, CA 125, CA 15-3, CA 50 and CEA in acute and chronic benign diseases in medical /surgical patients. In: New tumor markers and monoclonal antibodies (Klapdor R ed). Stuttgart New York, Georg Thieme Verlag, 1987, pp 287-290.
11. Ito K: CA 19-9 in mature cystic teratoma. Tohoku J Exp Med 172: 133-138, 1994.
12. Koch OM, Wust G: Unspecific elevation of tumour marker profiles in severe benign disease. In: New tumor markers and monoclonal antibodies (Klapdor R ed). Stuttgart New York, Georg Thieme Verlag, 1987, pp 291-296.
13. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fulner P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 5: 957-972, 1979.
14. Lahdenne P, Pitkanen S, Rajantie J, Kuusela P, Siimes MA, Lanning M, Heikinheimo M: Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: Developmental changes and use in pediatric germ cell tumors. Pediatr Res 38: 797-801, 1995.
15. Mikuni M, Makinoda S, Tanaka T, Okuda T, Domon H, Fujinoto S: Evaluation of tumor marker in ovarian dermoid cyst. Nippon Sanka Fujinka Gakkai Zasshi 42: 479-484, 1990.
16. Minami H, Itoyanagi N, Kubota F, Nakamura Y: A case of mediastinal mature teratoma presenting increases CA 19-9 level. Nippon Kyobu Geka Gakkai Zasshi 42: 2139-2143, 1994.
17. Mokovitzky J: The occurrence of the carbohydrate antigen 19-9 in the organism of man. In: Current tumor diagnosis: Applications, clinical relevance, research, trends (Klapdor R ed). Munchen Bern Wien New York, W. Zuckschwerdt Verlag, 1994, pp 808-810.
18. Motofi FK, Sesterhann MD, Davis CJ jr.: Pathology of testicular tumors. In: Principles and management of testicular cancer (Javadpour N ed). Stuttgart New York, Georg Thieme Verlag, 1987, pp 47-72.
19. Nagata H, Takahashi K, Yamane Y, Yoshino K, Shibukawa T, Kitao M: Abnormally high values of CA 125 and CA 19-9 in women with benign tumors. Gynecol Obstet Invest 28: 165-168, 1989.
20. nd ed, Munchen Wien Baltimore, Urban & Schwarzenberg, 1987, pp 217-220.
21. Sudo Y, Kobayashi M, Kako N, Iwabuchi T, Iwabuchi S, Koie H: Report of a case of bilateral adrenal teratoma with CA19-9 production. Nippon Geka Gakkai Zasshi 96: 489-491, 1994.
22. Von Kleist S, Hess Y, Kananeeh H: Comparative evaluation of four tumor markers, CA 242, CA19/9, TPA and CEA in carcinomas of the colon. Anticancer Res 12: 2325-2332, 1996.